Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 11:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 89 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Cerebrovascular Accident
Interventions
Magnesium Sulfate, Normal Saline
Drug
Lead sponsor
Jeffrey L. Saver
Other
Eligibility
40 Years to 95 Years
Enrollment
1,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Diabetes Mellitus, Type 1
Interventions
AT247, NovoLog, Fiasp
Drug
Lead sponsor
Arecor Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Type 2 Diabetes
Interventions
Degludec, Glargine, Aspart
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • New York, New York • Spokane, Washington
Conditions
Brain Metastases, Adult, Brain Metastases, Brain Cancer
Interventions
18F fluciclovine
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Conditions
Type 2 Diabetes
Interventions
Semaglutide, Insulin Degludec, Insulin aspart
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Colorectal Cancer
Interventions
5-Fluorouracil, Leucovorin, Capecitabine [Xeloda]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 14 more
Conditions
Melanoma
Interventions
fludeoxyglucose F 18, Positron emission tomography-computed tomography, 18F-fluorothymidine, Positron emission tomography-magnetic resonance imaging
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Anesthesia
Interventions
MTPI, Classic Induction
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Type 1 Diabetes Mellitus
Interventions
InsuPatch
Device
Lead sponsor
Insuline Medical Ltd.
Industry
Eligibility
12 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Early Phase 1 Interventional

PET/CT Imaging in COVID-19 Patients

NCT04376593
Conditions
COVID-19, SARS-CoV-2 Infection
Interventions
18F-αvβ6-BP
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Sacramento, California
Completed Not applicable Interventional Results available

Cerebral Edema in Pediatric Diabetic Ketoacidosis

NCT00629707
Conditions
Diabetic Ketoacidosis
Interventions
intravenous fluid treatment
Other
Lead sponsor
University of California, Davis
Other
Eligibility
8 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Sacramento, California
Conditions
Depression, Suicide
Interventions
0.2 mg/kg ketamine, placebo
Drug · Other
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Conditions
Cerebral Edema, Diabetic Ketoacidosis
Interventions
0.45% saline replacement fluid, 0.9% saline replacement fluid, 0.45% saline intravenous fluid, 0.9% saline Intravenous fluid
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 17 Years
Enrollment
1,389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
13
States / cities
Sacramento, California • Aurora, Colorado • Wilmington, Delaware + 10 more
Conditions
Malignant Neoplasms of Urinary Tract, Bladder Cancer
Interventions
Rocuronium, Sugammadex, Neostigmine, Glycopyrrolate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Diabetes
Interventions
slow fluid rate, fast fluid rate
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Day to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Autoimmune Basis for Postural Tachycardia Syndrome

NCT02725060
Conditions
Postural Orthostatic Tachycardia Syndrome, Postural Tachycardia Syndrome, Tachycardia, Arrhythmias, Cardiac, Autonomic Nervous System Diseases, Orthostatic Intolerance, Cardiovascular Diseases, Primary Dysautonomias
Interventions
phenylephrine, isoproterenol, 25 micro-Ci of radiation, Posture study with blood samples, 24-hour heart rhythm and blood pressure monitoring, Quantitative Axonal Sudomotor Reflex Testing, Autonomic function tests, Rebreathing test, Assessment of splanchnic capacitance, microneurography
Drug · Radiation · Procedure + 1 more
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Nashville, Tennessee
Completed Phase 1Phase 2 Interventional Results available

Treat COVID-19 Patients With Regadenoson

NCT04606069
Conditions
COVID-19, Lung Inflammation
Interventions
Regadenoson, Placebo Control
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes

NCT02121184
Conditions
Pregnancy, Labor Pain
Interventions
Routine oxytocin, Half-dose oxytocin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Multiple Sclerosis
Interventions
F-18 3F4AP
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Magnetic Resonance Angiography, Contrast Media
Interventions
Standard Injection Rate, Patient Tailored Injection Rate, gadolinium contrast
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Completed Phase 1 Interventional Accepts healthy volunteers

Glucagon Regulation of Glucose Metabolism

NCT04347252
Conditions
Insulin Secretion
Interventions
Glucagon
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Diabetes Mellitus, Type 1
Interventions
Control IQ + sleep or exercise activity with TI
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Louisville, Kentucky • Philadelphia, Pennsylvania • Seattle, Washington
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Pump (Medtronic Minimed Paradigm® VEO)
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia • Albany, New York • Syracuse, New York
Conditions
Healthy
Interventions
Midazolam Syrup, Midazolam Solution, Pirtobrutinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Daytona Beach, Florida